Page 72 - Read Online

Sabe et al. Vessel Plus 2024;8:2 https://dx.doi.org/10.20517/2574-1209.2023.95 Page 11 of 12

Financial support and sponsorship
This research was funded by the National Heart, Lung, and Blood Institute (NHLBI) 1F32HL160063-01
(Sabe SA); T32 GM065085 [J.A.](Xu CM, Banerjee D); NIH T32HL160517 [F.W.S] (Harris DD, Broadwin
M); 1R01HL133624 (Abid MR); 2R56HL133624-05 (Abid MR); R01HL46716 and R01HL128831 (Sellke
FW).

Conflicts of interest
All authors declared that there are no conflicts of interest.
Ethical approval and consent to participate
This study was approved by the RIH IACUC (#505821).

Consent for publication
Not applicable.

Copyright
© The Author(s) 2024.

REFERENCES
1. Lassaletta AD, Chu LM, Sellke FW. Therapeutic neovascularization for coronary disease: current state and future prospects. Basic Res

Cardiol 2011;106:897-909. DOI PubMed
2. Knuuti J, Wijns W, Saraste A, et al. 2019 ESC guidelines for the diagnosis and management of chronic coronary syndromes: the
task force for the diagnosis and management of chronic coronary syndromes of the European Society of Cardiology (ESC). Eur Heart J
2020;41:407-77. DOI
3. Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2019;380:347-57.
DOI PubMed
4. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med
2015;373:2117-28. DOI
5. Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med
2019;380:2295-306. DOI PubMed
6. Lim VG, Bell RM, Arjun S, Kolatsi-Joannou M, Long DA, Yellon DM. SGLT2 inhibitor, canagliflozin, attenuates myocardial
infarction in the diabetic and nondiabetic heart. JACC Basic Transl Sci 2019;4:15-26. DOI PubMed PMC
7. Baker HE, Kiel AM, Luebbe ST, et al. Inhibition of sodium-glucose cotransporter-2 preserves cardiac function during regional
myocardial ischemia independent of alterations in myocardial substrate utilization. Basic Res Cardiol 2019;114:25. DOI PubMed
PMC
8. Sayour AA, Korkmaz-Icöz S, Loganathan S, et al. Acute canagliflozin treatment protects against in vivo myocardial ischemia-
reperfusion injury in non-diabetic male rats and enhances endothelium-dependent vasorelaxation. J Transl Med 2019;17:127. DOI
PubMed PMC
9. Sabe SA, Xu CM, Sabra M, et al. Canagliflozin improves myocardial perfusion, fibrosis, and function in a swine model of chronic
myocardial ischemia. J Am Heart Assoc 2023;12:e028623. DOI PubMed PMC
10. Sauvé M, Ban K, Momen MA, et al. Genetic deletion or pharmacological inhibition of dipeptidyl peptidase-4 improves cardiovascular
outcomes after myocardial infarction in mice. Diabetes 2010;59:1063-73. DOI PubMed PMC
11. Kubota A, Takano H, Wang H, et al. DPP-4 inhibition has beneficial effects on the heart after myocardial infarction. J Mol Cell
Cardiol 2016;91:72-80. DOI
12. Bostick B, Habibi J, Ma L, et al. Dipeptidyl peptidase inhibition prevents diastolic dysfunction and reduces myocardial fibrosis in a
mouse model of Western diet induced obesity. Metabolism 2014;63:1000-11. DOI PubMed PMC
13. Sabe SA, Harris DD, Broadwin M, et al. Sitagliptin therapy improves myocardial perfusion and arteriolar collateralization in
chronically ischemic myocardium: a pilot study. Physiol Rep 2023;11:e15744. DOI PubMed PMC
14. Gonzalez J, Bates BA, Setoguchi S, Gerhard T, Dave CV. Cardiovascular outcomes with SGLT2 inhibitors versus DPP4 inhibitors and
GLP-1 receptor agonists in patients with heart failure with reduced and preserved ejection fraction. Cardiovasc Diabetol 2023;22:54.
DOI PubMed PMC
15. Lyu YS, Oh S, Kim JH, Kim SY, Jeong MH. Comparison of SGLT2 inhibitors with DPP-4 inhibitors combined with metformin in
patients with acute myocardial infarction and diabetes mellitus. Cardiovasc Diabetol 2023;22:185. DOI PubMed PMC
16. Oh M, Choi JH, Kim SO, et al. Comparison of empagliflozin and sitagliptin therapy on myocardial perfusion reserve in diabetic
patients with coronary artery disease. Nucl Med Commun 2021;42:972-8. DOI
17. Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the